Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Medically reviewed by Marla Anderson, MD Key Takeaways IV therapy delivers cancer medicine directly into a vein and often ...

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

In this exclusive MedPage Today video, Jorge Nieva, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles, discusses the growing trend of subcutaneous formulations ...

A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...

Switching from established intravenous (IV) therapy to subcutaneous infliximab was associated with high treatment persistence, stable clinical disease activity, and consistent faecal calprotectin ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in ...

(RTTNews) - Roche (RHHBY) said that its Tecentriq subcutaneous is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung, bladder, breast and liver ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...